The only industry-focused forum dedicated to facilitating the discovery, translation and acceleration of bacteriophage research into targeted therapeutics with clinically significant results.
As phage therapy offers an opportunity to tackle the ever-growing problem of antibiotic resistant infections, the 2nd Bacteriophage Therapy Summit returns to not only drive forward the translation of phage pharmacology into the clinic but also generate discussion around the direction that phage therapy is heading and how this can be commercialized and delivered into the hands of physicians and patients in need.
The 2nd Bacteriophage Therapy Summit is a dedicated scientific and networking forum for large pharma, biotechs and research institutes to capitalize on this re-emerging therapeutic class.
With a clear focus on overcoming the translational and development challenges of this re-emerging therapeutic class, join your peers to be part of the discussion to facilitate the translation of phage products into targeted, clinically successful therapeutics.
Early booking and group discounts apply, start-up and academic rates are available - see the website for details.
Conference + 2 Workshops - Industry: USD 3397.00,
Conference + 1 Workshop - Industry: USD 2898.00,
Workshop Only - Industry: USD 599.00,
Conference Only - Industry: USD 2399.00,
Conference + 2 Workshops - Academic/Start-Up: USD 2297.00,
Conference + 1 Workshop - Academic/Start-Up: USD 1998.00,
Conference Only - Academic/Start-Up: USD 1699.00,
Workshop Only - Academic/Start-Up: USD 399.00
Speakers: Greg Merril, Adaptive Phage Therapeutics, Duane Morris, Armata Pharmaceuticals, Carrie-Lynn Langlais Furr, Bacteria and Drug Development Consultants, Ales Strancar, BIA Separations, Chandrabali Ghose, Bioharmony Therapeutics, Sailaja Puttagunta, BiomX, Steven Theriault, Cytophage Technologies, Xavier Duportet, Eligo Bioscience, Eric Pelfrene, EMA, Rebecca Reindel, FDA, Scott Stibitz, FDA, Shawna McCallin, Hopitaux Universitaires de Genève, Daniel Stahm, International Health Management Associates, Tuval Ben-Yehezkel, Loop Genomics, Danish Malik, Loughborough University, Kevin Yehl, Massachusetts Institute of Technology, Conrad Lichtenstein, Nemesis Bioscience, Liesl Jeffers-Francis, North Carolina AandT State University, Nancy Tawil, Phagelux, Lorenzo Corsini, PhagoMed, James Cass, Phico Therapeutics, Jaroslaw Dastych, Proteon Pharmaceuticals, Vincent Fischetti, Rockefeller University, Paul Turner, Yale University